LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Find insight on Roche Holding, Novo Nordisk, Eli Lilly and more in the latest Market Talks covering Health Care.

Eli Lilly’s weight-loss pill enthusiasm wanes, impacting its stock. Early trading on August 8 saw the company's stock down by ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...